Is AGIO or AIM more undervalued in 2026?

CirclFi compares Agios Pharmaceuticals, Inc. (AGIO) and AIM ImmunoTech Inc. (AIM) using 13 institutional-grade valuation models. AGIO has a Quality of Company score of 6.0/10 while AIM scores 4.2/10.

Which is a better buy — AGIO or AIM?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AGIO and AIM valuations compare?

AGIO at $30.42 and AIM at $0.44 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AGIO vs AIM Valuation Comparison 2026 — Intrinsic Value Analysis

AGIO

Biotechnology

Agios Pharmaceuticals, Inc.

Quality

6.0

out of 10

Value Trap

SAFE

Price

$30.42

Last close

Models

12/13

Active

AIM

Biotechnology

AIM ImmunoTech Inc.

Quality

4.2

out of 10

Value Trap

LOW

Price

$0.44

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	AGIO Fair Value	AGIO Upside	AIM Fair Value	AIM Upside
Bayesian DCF	Intrinsic	$8.83	-71.0%	$0.14	-66.9%
Earnings Power Value	Intrinsic	$3.81	-86.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$14.88	-51.1%	$1.51	+245.6%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AGIO vs AIM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AGIO vs AIM — Which Stock Is More Undervalued?

AGIO scores higher with a 6.0/10 quality rating vs AIM's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Agios Pharmaceuticals, Inc. (AGIO) and AIM ImmunoTech Inc. (AIM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AGIO currently trades at $30.42 with a QOC of 6.0/10, while AIM trades at $0.44 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).